



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/17, C12N 5/00	A2	(11) International Publication Number: WO 99/45949 (43) International Publication Date: 16 September 1999 (16.09.99)
(21) International Application Number: PCT/US99/04003 (22) International Filing Date: 24 February 1999 (24.02.99) (30) Priority Data: 09/037,118 9 March 1998 (09.03.98) US (71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). (72) Inventors: WOOD, Clive, R.; 2 Hawthorne Place #17R, Boston, MA 02114 (US). FITZ, Lori, Jo; 13 Palmer Street, Arlington, MA 02174 (US). (74) Agent: LAZAR, Steven, R.; American Home Products Corporation, Legal Affairs, Patent and Trademark Dept.-2B, One Campus Drive, Attn.: Kay E. Brady, Parsippany, NJ 07054 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: USE OF FOLLISTATIN TO MODULATE GDF-8 AND BMP-11 (57) Abstract Methods are provided for the modulation of the effects of GDF-8 and BMP-11, particularly on neural and muscular disorders administration of follistatin for treating neural, muscle, disorders which are characterized by an abnormality in the levels or activity of GDF-8 or BMP-11.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

USE OF FOLLISTATIN TO MODULATE GDF-8 AND BMP-11

5

FIELD OF THE INVENTION

The present invention relates to use of follistatin to modulate the activity of a growth and differentiation factor [GDF] known as GDF-8. More particularly, the invention relates to use of follistatin for treating neural and muscle, disorders which are related to modulation of the levels or activity of GDF-8 or closely related factors, including bone morphogenetic protein-11 [BMP-11], also known as GDF-11.

BACKGROUND OF THE INVENTION

Bone morphogenetic proteins (BMPs) and growth/differentiation factors (GDFs) are part of a family of proteins which have been identified as having the ability to induce the growth, formation, differentiation and maintenance of various tissues, including bone, cartilage, tendon/ligament, muscle, neural, and various organs. BMPs and GDFs are subfamilies within the TGF- β superfamily.

The TGF- β superfamily of proteins have been shown to bind to serine/threonine kinase receptors. Massague, Cell, 69:1067-1070 (1992); Attisano et al., Cell 68:97-108 (1992); Lin et al., Cell, 68:775-785 (1992); Wang et al., Cell 67:797-805 (1991). Similarly, activin receptors have been isolated and characterized as a predicted transmembrane serine kinase. Mathews et al., Cell 65:973-982 (1991); Nakamura et al., J. Biol. Chem. 267:18924-18928 (1992). Ebner et al., Science, 260:1344-1348 (1993) describe the existence of Type I and Type II TGF- β receptors, and the effects of the Type I receptor on binding of TGF- β to the Type II receptor.

Follistatin is a protein which has been identified as a molecule which is able to bind to activin, another member of the TGF- β superfamily, and as a possible antagonist of activin. United States Patent 5,545,616. Accordingly, follistatin has been suggested for possible use to predict and/or prevent preterm labor and to suppress FSH secretion from the pituitary [US Patent 5,545,616]; to have inhibin like activity [United States Patent 5,041,538]; and for use in rheumatoid arthritis [AU9675056, Kaneka Corp]

5

SUMMARY OF THE INVENTION

Accordingly, the present invention provides methods for modulating the effects on cells of a protein selected from the group consisting of growth and differentiation factor 8 [GDF-8] and bone morphogenetic protein 11 [BMP-11], said method comprising administering to said cells an effective amount of follistatin. The invention further provides methods for blocking the effects on cells of GDF-8 or BMP-11 and methods for treating a disorder associated with neural or muscular effects of GDF-8 or BMP-11, said method comprising administering to said cells an effective amount of follistatin.

In one embodiment, the present invention comprises methods of modulating the production and/or activity of GDF-8 or BMP-11, thereby affecting the growth, formation, differentiation and maintenance of cells using a follistatin protein, or a DNA molecule encoding a follistatin protein. The present invention further comprises treatment of disorders which are associated with the production, metabolism and activity of GDF-8 or BMP-11. Preferred embodiments include treatment of diseases and disorders involving neural or neuronal and muscle cells and tissue. These disorders include neurodegenerative and musculodegenerative diseases, such as muscle or nerve wasting, muscle or nerve atrophy, amyotrophic lateral sclerosis, Alzheimer's Disease, Parkinson's Disease and muscular dystrophy. The present invention further includes the use of follistatin for the treatment of traumatic or chronic injury to the spinal cord, or to the nerve or muscle system.

DETAILED DESCRIPTION OF THE INVENTION

TGF- β protein, such as BMPs and GDFs, are characterized by their ability to promote, stimulate or otherwise induce the growth, formation, differentiation and maintenance of various tissues, including bone, cartilage, tendon/ligament, muscle, neural, and various organs. GDF-8 has been shown to exhibit particular activity on muscle, adipocyte and neural tissue. BMP-11 has been shown to exhibit activity on neural cells, particularly on neuronal cells.

Two forms of follistatin (FS) are produced as a result of alternative splicing. These forms are FS-288 and FS-315. The FS-315 form has also been shown to be proteolytically processed to form FS-303 (Sugino et al., J.Biol. Chem.

5 268:15579(1993)). Recombinant forms of each of these molecules are expected to have different properties (Sumitomo et al., Biochem. Biophys. Acta 208:1(1995)) and are envisaged to be useful for inhibiting the action of GDF-8 and BMP-11 .

 The expected properties of follistatin, in light of the present showing, include differential ability to interact with cell surfaces ,and bind heparin and heparan sulphate
10 proteoglycans (Nakamura et al., J. Biol. Chem. 266:19432 (1991); Sumitomo et al., Biochem Biophys. Acta 208:1 (1995)). These properties may be suboptimal in the FS used for therapeutic use. As a consequence, site-directed mutagenesis may be used to alter this property. Specifically, this can involve changing or deleting the basic residues responsible for heparin binding, at residues 72-86 (Inouye et al., Mol Cell. Endocrinol.
15 90:1(1992)).

 Follistatin is useful, among other uses, for the identification of BMPs, the identification of further BMP receptors, and the identification of ligands or molecules, including antibodies, which are able to mimic the binding characteristics of BMPs. These ligands may act as agonists or antagonists, depending upon the individual ligand.
20 The ability of follistatin to block or modulate the activity of GDF-8 and BMP-11 may be characterized in an assay for BMP activity, such as the animal cap assay, described at Example 2 below. The follistatin molecules are also useful in inhibiting the effects of GDF-8 and BMP-11, where such inhibition is desired.

 Because of the known activities of GDF-8 and BMP-11, the present invention
25 will find use in treating muscle-related disorders, diseases of the nervous system (including infections), vascular disorders, trauma, metabolic derangements, demyelinating diseases (including multiple sclerosis), neuronal diseases (including Alzheimer's disease , Parkinson's disease and Huntington's chorea; and including motor
30 neuron diseases such as amyotrophic lateral sclerosis, primary lateral sclerosis and Werdnig-Hoffmann disease), epilepsy, syringomyelia, peripheral neuropathy, congenital anomalies and tumors. Muscle-related conditions for treatment include without limitation muscular dystrophies (such as severe and benign X-linked muscular dystrophy, limb-girdle dystrophy, facioscapulohumeral dystrophy, myotonic dystrophy, distal muscular dystrophy, progressive dystrophic ophthalmoplegia, oculopharyngeal
35 dystrophy and Fukuyama-type congenital muscular dystrophy), congenital myopathy,

5 myotonia congenital, familial periodic paralysis, paroxysmal myoglobinuria, myasthenia gravis, Eaton-Lambert syndrome, secondary myasthenia, denervation atrophy.

Follistatin proteins useful in the present invention include human follistatin, disclosed in Shimasaki et al., PNAS:USA 85:4218-4222 (1988); porcine follistatin, disclosed in Ueno et al., PNAS:USA 84:8282-8286 (1987); and bovine follistatin,
10 disclosed in Robertson et al., Biochem. Biophys. Res. Commun. 149:744-749 (1987). The disclosures of each of these publications is hereby incorporated by reference herein. In addition, truncated polypeptides which comprise partial fragments of the full follistatin polypeptides, and which retain the ability to bind to GDF-8 and BMP-11, may also be useful for the present invention. In particular, functional fragments of follistatin
15 sequences, which maintain the ability to modulate, block or otherwise affect GDF-8 and/or BMP-11 activity, are useful for the methods of the present invention. The identification of a partial follistatin polypeptide as a functional fragment of follistatin may readily be determined, for example, using the assay described in Example 2.

The present invention also includes fusions of follistatin with other molecules.
20 This includes the fusion of FS-288, FS-315 or FS-303 sequences with the *hinge*, *CH2* and *CH3* domains of a human immunoglobulin gamma isotype, *e.g.*, gamma 1 or 4. Such a fusion protein is expected to produce a dimeric molecule, with the improved pharmacokinetics expected for an immunoglobulin Fc fusion. In addition, the constant domains or secretory tailpieces of *alpha* or *mu* immunoglobulin heavy chains may be
25 fused to FS in order to generate polymeric forms of FS.

The component portion of FS responsible for interacting with GDF-8 and BMP-11 can be identified and used to generate functional fragments of FS, fusion proteins, or as the basis for other therapeutic utilities. The human FS gene contains four domains each encoded on a separate exon, in addition to an exon encoding a N-terminal signal
30 sequence, and an exon encoding the C-terminal extension that results in FS-315 (Shimasaki et al., Proc. Natl. Acad. Sci USA 85:4218(1995)). The regions responsible for GDF-8 and/or BMP-11 binding can be determined and prepared by the methods described in Example 3.

For use in the methods of the present invention, the purified follistatin proteins
35 and functional fragments thereof may be produced through purification from native

5 tissues, or recombinantly by culturing a host cell transformed with a DNA sequence comprising the DNA coding sequence described in any of the above publications. In addition to the native DNA coding sequences, coding sequences which can be used include sequences which code for the above, but which differ in codon sequence due to the degeneracies of the genetic code or allelic variations (naturally-occurring base
10 changes in the species population which may or may not result in an amino acid change), as well as DNA sequences which hybridize under stringent hybridization conditions [see, T. Maniatis et al, Molecular Cloning (A Laboratory Manual), Cold Spring Harbor Laboratory (1982), pages 387 to 389] to the DNA sequences described in the above publications and encode a protein having the ability to bind to GDF-8 or
15 BMP-11. Variations in the DNA sequences disclosed in the above publications which are caused by point mutations or by induced modifications (including insertion, deletion, and substitution) to enhance the activity, half-life or production of the follistatin polypeptides encoded thereby are also useful for the present invention.

The present invention may include gene therapy, in which transfection of cells
20 with DNA molecules encoding follistatin or functional fragments thereof is made in order to achieve binding of the follistatin to GDF-8 and/or BMP-11 present within the transfected cells or in the environment of the transfected cells, and thereby modulate or block the effects of GDF-8 and/or BMP-11 on those cells. For example, cells which express the follistatin proteins may reduce or eliminate the effects of an excess of GDF-
25 8 or BMP-11 in an organism or cell. The increased follistatin may be desirable for minimizing negative effects of GDF-8 or BMP-11, or may act as a complex with GDF-8 or BMP-11 to enhance or increase activity.

Follistatin proteins or functional fragments thereof may also be useful in a process for isolating GDF-8 or BMP-11 in a purification process. In such a process,
30 follistatin may be incorporated into a column or a resin which may be used for the commercial production of GDF-8 or BMP-11 from tissue samples or via recombinant processes. The follistatin or functional fragments thereof are used to bind to the GDF-8 or BMP-11, and later subjected to conditions which result in the release of said bound protein.

5 The present invention includes therapeutic methods comprising administering a follistatin containing composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is preferably in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the desired
10 site. Therapeutically useful agents, such as growth factors (e.g., BMPs, TGF- β , FGF, IGF), cytokines (e.g., interleukins and CSFs) and antibiotics, may also optionally be included in or administered simultaneously or sequentially with the Follistatin composition in the methods of the invention.

 There is a wide range of methods which can be used to deliver the cells
15 expressing follistatin proteins to a site for use in modulating a GDF-8 or BMP-11 response. In one embodiment of the invention, the cells expressing follistatin protein can be delivered by direct application, for example, direct injection of a sample of such cells into the site of tissue damage. In a particular embodiment, these cells can be purified. In a preferred embodiment, the cells expressing follistatin protein can be
20 delivered in a medium or matrix which partially impedes their mobility so as to localize the cells to a site of injury. Such a medium or matrix could be semi-solid, such as a paste or gel, including a gel-like polymer. Alternatively, the medium or matrix could be in the form of a solid, preferably, a porous solid which will allow the migration of cells into the solid matrix, and hold them there while allowing proliferation of the cells.

25 In a method of the present invention, the cells expressing follistatin are applied in the desired site as described above, and GDF-8 or BMP-11 is applied. The factor may be applied simultaneously or immediately following application of the cells expressing follistatin. The BMP may be applied in manners known in the art, such as described in the above patents, as well as in United States Patent 5,171,579, the
30 disclosure of which is also hereby incorporated by reference.

Expression of Follistatin Protein

 In order to produce follistatin protein, the DNA encoding the desired protein is transferred into an appropriate expression vector and introduced into mammalian cells or other preferred eukaryotic or prokaryotic hosts by conventional genetic engineering

5 techniques. The presently preferred expression system for biologically active recombinant follistatin protein is stably transformed mammalian cells.

The following examples detail presently preferred embodiments of the present invention. Numerous modifications and variations in practice thereof are expected to occur to those skilled in the art upon consideration of these descriptions. Those
10 modifications and variations are believed to be encompassed within the claims appended hereto. The examples do not in any way limit the invention.

EXAMPLES

EXAMPLE 1. BIAcore binding assay:

15 Purified follistatin was coupled to a carboxymethyl dextran layer of a CM5 research grade chip on a Biacore 2000 instrument using standard amine coupling procedures according to the manufacturer's instructions. The buffer used for immobilization was 10 mM sodium acetate pH 4. Typically about 7,000 response units (RU) of follistatin were immobilized by this procedure. Purified BMP and GDF
20 proteins were each injected over the immobilized follistatin for 10 minutes at 2 µl/min. The running buffer used for screening was 10 mM sodium phosphate pH 7.4, 300 mM sodium chloride, 3.4 mM ethylenediaminetetra-acetic acid, 0.005% (v/v) Tween 20 and the temperature was maintained at 22°C. Binding was quantified as an increase in RU at 60 sec after the end of the injection compared to a baseline established 20 sec prior
25 to injection. Specific binding was shown by coinjection of soluble follistatin and the BMP-11 and GDF-8 proteins.

Results:

Results from the Biacore screen showed that both GDF-8 and BMP-11 bound follistatin. This binding was comparable to the positive control, activin. The binding
30 was specific, as demonstrated by the fact that no binding was observed when GDF-8 or BMP-11 was preincubated and coinjected with excess soluble follistatin.

5 **EXAMPLE 2: Animal Cap Assay Method**

 The *Xenopus* animal cap assay has been used to assess the biological activity of BMP proteins. *Xenopus* eggs were fertilized *in vitro* and allowed to develop until the blastula stage. The ectodermal or animal cap of the embryo was excised and cultured in media containing the protein of interest for 5-6 hours. The explants were then
10 transferred to fresh media without protein. The animal caps were cultured overnight and the activity of the protein was evaluated the next day by morphology, histology, and RT-PCR using molecular markers of mesoderm, neural tissue, and endoderm.

Animal Cap Assay Results

 Both GDF-8 and BMP-11 caused animal caps to elongate and induced dorsal mesoderm
15 (muscle) and neural tissue at doses (50ng/ml) comparable to that for factors that have been shown previously to induce these tissues (e.g., activin). Follistatin was able to inhibit the ability of both GDF-8 and BMP-11 to induce elongation and mesodermal tissue in animal caps. GDF-8 was blocked by a 5 fold excess of follistatin (100ng/ml GDF-8 and 500ng/ml follistatin) while BMP-11 was blocked by a 10 fold excess of
20 follistatin (BMP-11 50ng/ml and 500ng/ml follistatin). Together, the Biacore binding results and inhibition on the *Xenopus* animal cap assay demonstrate that follistatin is an antagonist of GDF-8 and BMP-11, and is able to modulate the activity of these two factors.

EXAMPLE 3: Determination of Functional Fragments of Follistatin

25 Functional fragments of Follistatin, and the components of Follistatin that are necessary for the preparation thereof, are defined by generating a series of FS mutants each with an additional exon deleted from the 3' end. The six exons of FS are numbered 1 to 6. The mutants will consist of exons 1-5, 1-4, 1-3 and 1-2 and the binding of each form will be compared with wild-type FS (1-6). This will identify the
30 domain or domains responsible for ligand binding. Specific residues that are critical for binding to ligand will then be identified using site-directed mutagenesis.

 The 1-5, 1-4, 1-3 and 1-2 forms will be generated by using oligonucleotide primers and the polymerase chain reaction (PCR). The template for this amplification will be the FS cDNA, either from a plasmid clone or as the result of random hexamer-
35 primed first strand cDNA synthesis from primary tissue poly A+ RNA (e.g., from ovary

5 RNA). A forward (5') primer based on the start codon of FS will be used in each amplification, and combined with a reverse (3') primer that anneals to the 3' coding sequence of the final exon (*e.g.*, exon 5 for the 1-5 form) and introduces a stop codon immediately after the final exon. Recognition sequences of restriction endonucleases will also be added to the 5' end of each primer to facilitate molecular cloning of the
 10 PCR product into an expression vector. PCR conditions and components will be chosen to minimize the introduction of point mutations, and the resulting clones will be analyzed by nucleotide sequencing to ensure the correct FS sequence is present in each construct.

The forward primer is called FS-forward. The reverse primer for generating 1-5
 15 is called FS-reverse 5; for 1-4 is called FS-reverse 4; for 1-3 is called FS-reverse 3 ;and for 1-2 is called FS-reverse 2. Potential sequences for these primers are given below. The FS sequences responsible for interacting with GDF-8, BMP-11 and activin may be identical. If the binding sites are discrete or overlapping, mutagenesis can be used to abolish binding to specific FS ligands. This can be achieved by alanine-scanning
 20 mutagenesis and testing of each mutant for binding to each of the three ligands.

FS-forward: 5'-dCCAGGATGGTCCGCGCGAGG-3' [SEQ ID NO:1]

FS-reverse 5: 5'-dTCAGTTGCAAGATCCGGAGT-3' [SEQ ID NO:2]

FS-reverse 4: 5'-dTCATTTGATACACTTTCCTCAT-3' [SEQ ID NO:3]

FS-reverse 3: 5'-dTCACTTTTTACATCTGCCTTGGT-3' [SEQ ID NO:4]

25 FS-reverse 2: 5'-dTCATTCTTTACAGGGGATGCAGT-3' [SEQ ID NO:5]

Using techniques and primers similar to those described above, a series of FS mutants each with an additional exon deleted from the 5' end is generated in order to determine whether the N-terminal portion of the Follistatin protein are required for functional fragments of Follistatin. These mutants will consist of exons 3-6, 4-6, 5-6
 30 and 6, and the binding of each form will also be compared with wild-type FS (1-6). The first exon, including the signal sequence, will be included on each construct to facilitate the proper secretion of each molecule.

5 Claims

We claim:

1. A method for modulating the effects on cells of a protein selected from the group consisting of growth and differentiation factor 8 [GDF-8] and bone morphogenetic protein 11 [BMP-11], said method comprising administering to said
10 cells an effective amount of follistatin.
2. The method of claim 1, wherein the protein is GDF-8.
3. The method of claim 1, wherein the protein is BMP-11.
4. A method for blocking the effects on cells of a protein selected from the group consisting of growth and differentiation factor 8 [GDF-8] and bone
15 morphogenetic protein 11 [BMP-11], said method comprising administering to said cells an effective amount of follistatin.
5. The method of claim 4, wherein the protein is GDF-8.
6. The method of claim 4, wherein the protein is BMP-11.
7. A method for treating a disorder associated with neural or muscular effects
20 of a protein selected from the group consisting of growth and differentiation factor 8 [GDF-8] and bone morphogenetic protein 11 [BMP-11], said method comprising administering to said cells an effective amount of follistatin.
8. The method of claim 7, wherein the protein is GDF-8.
9. The method of claim 7, wherein the protein is BMP-11.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: WOOD, Clive R.
FITZ, LORI
- (ii) TITLE OF INVENTION: USE OF FOLLISTATIN TO MODULATE GROWTH
AND DIFFERENTIATION FACTOR-8 [GDF-8] AND BONE
MORPHOGENETIC PROTEIN [BMP-11]
- (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: GENETICS INSTITUTE, INC.
 - (B) STREET: 87 CambridgePark Drive
 - (C) CITY: Cambridge
 - (D) STATE: Massachusetts
 - (E) COUNTRY: USA
 - (F) ZIP: 02140
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE: herewith
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: LAZAR, STEVEN R.
 - (B) REGISTRATION NUMBER: 32,618
 - (C) REFERENCE/DOCKET NUMBER: GI 5327-PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (617) 665-8260
 - (B) TELEFAX: (617) 876-5851

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCAGGATGGT CCGCGCGAGG

20

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TCAGTTGCAA GATCCGGAGT

20

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TCATTTGATA CACTTCCCT CAT

23

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCACTTTTTA CATCTGCCTT GGT

23

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 23 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCATTCTTTA CAGGGGATGC AGT

23



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/17, C12N 5/00	A3	(11) International Publication Number: WO 99/45949 (43) International Publication Date: 16 September 1999 (16.09.99)
(21) International Application Number: PCT/US99/04003 (22) International Filing Date: 24 February 1999 (24.02.99) (30) Priority Data: 09/037,118 9 March 1998 (09.03.98) US (71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). (72) Inventors: WOOD, Clive, R.; 2 Hawthorne Place #17R, Boston, MA 02114 (US). FITZ, Lori, Jo; 13 Palmer Street, Arlington, MA 02174 (US). (74) Agent: LAZAR, Steven, R.; American Home Products Corporation, Legal Affairs, Patent and Trademark Dept.-2B, One Campus Drive, Attn.: Kay E. Brady, Parsippany, NJ 07054 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 18 November 1999 (18.11.99)
(54) Title: USE OF FOLLISTATIN TO MODULATE GDF-8 AND BMP-11 (57) Abstract <p>Methods are provided for the modulation of the effects of GDF-8 and BMP-11, particularly on neural and muscular disorders administration of follistatin for treating neural, muscle, disorders which are characterized by an abnormality in the levels or activity of GDF-8 or BMP-11.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/04003

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K38/17 C12N5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	THOMSEN G H: "Antagonism within and around the organizer: BMP inhibitors in vertebrate body patterning" TRENDS IN GENETICS, vol. 13, no. 6, 1 June 1997 (1997-06-01), page 209-211 XP004065308 ISSN: 0168-9525 the whole document ---	1-9
Y	WO 95 10611 A (HARVARD COLLEGE) 20 April 1995 (1995-04-20) the whole document ---	1-9
Y	US 5 700 911 A (CELESTE ANTHONY J ET AL) 23 December 1997 (1997-12-23) the whole document ---	1-9
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 September 1999

Date of mailing of the international search report

05/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hagenmaier, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/04003

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 26892 A (GENETICS INST) 24 November 1994 (1994-11-24) the whole document ---	1-9
Y	WO 94 21681 A (UNIV JOHNS HOPKINS MED ; LEE SE JIN (US); MCPHERRON ALEXANDRA C (US) 29 September 1994 (1994-09-29) the whole document ---	1-9
Y	A FAINSOD ET AL: "THE DORSALIZING AND NEURAL INDUCING GENE FOLLISTATIN IS AN ANTAGONIST OF BMP-4" MECHANISMS OF DEVELOPMENT, vol. 1, no. 63, 1 April 1997 (1997-04-01), page 39 50 XP002076023 ISSN: 0925-4773 the whole document ---	1-9
A	GB 2 306 481 A (UNIV MANCHESTER) 7 May 1997 (1997-05-07) the whole document ---	
A	US 5 545 616 A (WOODRUFF TERESA K) 13 August 1996 (1996-08-13) the whole document ---	
T	GAMER ET AL.: "A NOVEL BMP EXPRESSED IN DEVELOPING MOUSE LIMB, SPINAL CORD, AND TAIL BUD IS A POTENT MESODERM INDUCER IN XENOPUS EMBRYOS" DEVELOPMENTAL BIOLOGY, vol. 208, April 1999 (1999-04), pages 222-232, XP002115687 the whole document -----	1-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/04003

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 7-9 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/04003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9510611 A	20-04-1995	AU 701623 B AU 7980694 A CA 2174098 A EP 0726948 A JP 9503673 T	04-02-1999 04-05-1995 20-04-1995 21-08-1996 15-04-1997
US 5700911 A	23-12-1997	US 5639638 A AU 678582 B AU 6910594 A BR 9406715 A EP 0698094 A FI 955419 A JP 9501304 T NO 954492 A WO 9426892 A	17-06-1997 05-06-1997 12-12-1994 06-02-1996 28-02-1996 08-01-1996 10-02-1997 08-11-1995 24-11-1997
WO 9426892 A	24-11-1994	AU 678582 B AU 6910594 A BR 9406715 A EP 0698094 A FI 955419 A JP 9501304 T NO 954492 A US 5639638 A US 5700911 A	05-06-1997 12-12-1994 06-02-1996 28-02-1996 08-01-1996 10-02-1997 08-11-1995 17-06-1997 23-12-1997
WO 9421681 A	29-09-1994	CA 2157577 A EP 0690873 A JP 9507829 T US 5827733 A	29-09-1994 10-01-1996 12-08-1997 27-10-1998
GB 2306481 A	07-05-1997	AU 7313896 A CA 2235412 A EP 0855916 A WO 9715321 A	15-05-1997 01-05-1997 05-08-1998 01-05-1997
US 5545616 A	13-08-1996	NONE	